Manufacturer: Dragon Pharma
Pharmaceutical name: Retatrutide
Pack: 1 vial (10 mg)
Retatrutide (LY3437943) TFA is a peptide that acts as a triple agonist for the glucagon receptor (GCGR), the glucosedependent insulinotropic polypeptide receptor (GIPR), and the glucagon-like peptide-1 receptor (GLP-1R). It inhibits human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643, and 0.775 nM, respectively. Retatrutide TFA is utilized for obesity research.
Alongside weight loss, retatrutide has shown potential in enhancing glycemic control, with 72% of participants reverting from prediabetes to normoglycemia. Additionally, the medication positively affected cardiovascular health markers, leading to significant decreases in both systolic and diastolic blood pressure as well as an improved lipid profile.
Mild-to-moderate side effects and drug mechanism
Among the most frequently reported side effects were mild-to-moderate gastrointestinal issues, mainly during the dose escalation phase. Researchers believe that the drug’s effectiveness stems from its agonistic interactions with the glucagon, GIP, and GLP-1 receptors, suggesting a potential role for these receptors in the therapeutic action of retatrutide.